Growing evidence points to a critical role for epigenetic mechanisms in diverse aspects of human health and disease, including neurodegenerative and neuropsychiatric disorders. This role includes fundamental cellular processes ranging from neurogenesis to synaptogenesis, with significant implications for the development of novel therapeutics to treat and ideally prevent disease pathophysiology. However, despite dramatic advances in our ability to observe the epigenome and transcriptome, our ability to perturb the epigenome and manipulate transcriptional programs with precise temporal control and spatial resolution remains severely limited due to the pleiotropic effects of most existing pharmacological probes and the lack of suitable genetic tools. To overcome these limitations and enable targeting specific cell types within neurocircuits, we propose an integrated, multidisciplinary approach-spanning synthetic chemistry to neurobiology- combining innovative, and scalable 'chemical optoepigenetic'technologies together with epigenome and transcriptome analysis in human and mouse neurons. Our strategy for neuromodulation exploits photoswitchable compounds with fast thermal relaxation kinetics that possess slow-binding kinetics with their epigenetic targets. Using the family of class I histone deacetylase (HDAC)-containing chromatin-modifying complexes, which our work has demonstrated as key regulators of chromatin-mediated neuroplasticity, to advance the testing of this methodology, the specific aims of the proposed project are to: 1) synthesize, characterize and optimize the physical properties, biochemical potency and selectivity of optoepigenetic probes capable of light-dependent inhibition of the deacetylase activity of neuronal chromatin-modifying complexes containing different class I HDAC isoforms;2) determine the epigenome and transcriptome changes in cultured human stem cell-derived neurons after precise temporal manipulation of different HDAC complexes;and 3) use the novel optoepigenetic probes to temporally manipulate the epigenome of spatially defined mouse neurons to enhance synaptogenesis and modulate hippocampal circuit function. Overall, by providing significant improvements in spatiotemporal control of HDAC activity in combination with advances in the generation of isoform and complex-selective HDAC inhibitors, we anticipate our approach will limit the pleiotropic effects of currently available small molecule tools. Through selective manipulation of the epigenome in specific regions of neurocircuits, we anticipate being able to significantly improve our understanding of how specific temporal regulation of epigenetic states affects neuroplasticity and to be able to delineate the contribution of epigenetic mechanisms in defined neuronal subtypes within neurocircuits. Importantly, our approach developing chemical optoepigenetic probes is broadly applicable to manipulating epigenetic regulatory mechanisms and could be scaled to enable the assembly of a molecular tool kit for combinatorial optoepigenetic studies. Such tools could have wide applicability in the field of neuroepigenetics and help advance efforts to develop improved therapeutics targeting neuroplasticity.

Public Health Relevance

Growing evidence points to a critical role for epigenetic mechanisms, in particular the post-translational modification of histone proteins, in diverse aspects of human health and disease ranging from cognitive disorders to cancer. The proposed studies will take an integrated, multidisciplinary approach-spanning synthetic chemistry to neurobiology-to create innovative chemical tools that can be optically controlled to provide precise spatiotemporal regulation of epigenetic mechanisms implicated in governing neuroplasticity. As an example of advancing this technology for neuromodulation, the focus will be on manipulating the enzymatic activity of histone deacetylases (HDACs) whose activity controls the expression of key genes involved in synaptogenesis and synaptic plasticity and therefore are potential targets for novel therapeutic development for a range of brain disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS088209-01
Application #
8749559
Study Section
Synthetic and Biological Chemistry B Study Section (SBCB)
Program Officer
Riddle, Robert D
Project Start
2014-06-01
Project End
2019-04-30
Budget Start
2014-06-01
Budget End
2015-04-30
Support Year
1
Fiscal Year
2014
Total Cost
$394,763
Indirect Cost
$167,888
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199